Could “single cell genomics” replace Gleason grading in prostate cancer risk evaluation?

According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …

Height IS a risk factor for higher-risk prostate cancer

A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …

A high-grade ego with high-grade prostate cancer

For those who have either forgotten or never knew who Craig Venter is or was, here’s an update: he recently had surgical treatment for “high-grade” prostate cancer. … READ MORE …

New grade group system predicts risk for prostate cancer-specific mortality

According to a report on the Renal & Urology News web site this morning, a new paper about to be published on line in European Urology (by He et al.) has shown that the new ISUP staging system can be used to project risk for prostate cancer-specific mortality, “regardless of treatment received or clinical stage at diagnosis”. … READ MORE …

A new urine test to assess risk for prostate cancer?

Apparently a newly developed type of urine test — an RNA-based “urine exosome gene expression assay” — has the potential to differentiate between risk for high-grade prostate cancer (Gleason score ≥ 7) and low-grade prostate cancer (Gleason score 6) or benign disease. … READ MORE …

mpMRIs vs. biopsies for repeat evaluations on active surveillance

A question on the minds of many prostate cancer researchers and clinicians (not to mention their patients) is if and when we may be able to replace repeat systematic prostate biopsies for patients on active surveillance (or seeking to start on active surveillance) with the significantly less invasive multiparametric MRIs (mpMRIs). … READ MORE …

Intraductal carcinoma of the prostate: of risk, outcomes, and Gleason scores

In a recent article in the American Journal of Surgical Pathology, Khani and Epstein have argued that patients initially diagnosed with intraductal carcinoma of the prostate (IDC-P) should have this reported as a separate class of prostate cancer, with no reference to the patients’ Gleason scores. … READ MORE …